Hybrid closed-loop artificial pancreas system improves blood sugar control better than insulin injections in hospitalized type 1 diabetes

Evidence Suggest

• HCL system significantly increased time in range compared to multiple daily injections (87% vs 65%, p<0.05)
• Automated insulin delivery reduced severe low blood sugar events (glucose <3.0 mmol/L) by 78%
• Blood sugar fluctuations were smoother throughout the day and night, especially after meals and during sleep

Who this applies to

This case involved a 28-year-old woman with long-standing type 1 diabetes (17 years), elevated HbA1c (11.9%), history of poor glucose control, and frequent hypoglycemia. The findings may be most relevant for adults with type 1 diabetes who have difficulty achieving stable glucose control with insulin injections, particularly those experiencing frequent low blood sugar episodes.

Keep in Mind

This is a single case report, not a controlled study with multiple participants, so the results should be interpreted cautiously. The patient was hospitalized and closely monitored, which may not reflect typical outpatient care. The Android-based hybrid closed-loop system used is a do-it-yourself (DIY) system that is not commercially approved or regulated in China, and requires significant technical knowledge to set up and maintain. The cost of insulin pumps and CGM devices is not covered by medical insurance in China, limiting accessibility for most patients.

Between the Lines

• Case report of only one patient - results may not apply to all people with type 1 diabetes
• Short observation period of just 7 days for each treatment method
• Patient was hospitalized, so results may differ in outpatient or real-world settings
• AndroidAPS system is not commercially approved in China and requires technical expertise to set up